<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> are a group of <z:e sem="disease" ids="C1521860" disease_type="Disease or Syndrome" abbrv="">hematologic disorders</z:e> that often evolve into secondary <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>The genetic changes that underlie progression from the <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> to <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> are not well understood </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We performed whole-genome sequencing of seven paired samples of skin and bone marrow in seven subjects with <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> to identify <z:hpo ids='HP_0001428'>somatic mutations</z:hpo> specific to <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>We then genotyped a bone marrow sample obtained during the antecedent <z:hpo ids='HP_0002863'>myelodysplastic-syndrome</z:hpo> stage from each subject to determine the presence or absence of the specific <z:hpo ids='HP_0001428'>somatic mutations</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>We identified recurrent mutations in coding genes and defined the clonal architecture of each pair of samples from the <z:hpo ids='HP_0002863'>myelodysplastic-syndrome</z:hpo> stage and the <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary-AML</z:e> stage, using the allele burden of hundreds of mutations </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Approximately 85% of bone marrow cells were clonal in the <z:hpo ids='HP_0002863'>myelodysplastic-syndrome</z:hpo> and <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary-AML</z:e> samples, regardless of the myeloblast count </plain></SENT>
<SENT sid="6" pm="."><plain>The <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary-AML</z:e> samples contained mutations in 11 recurrently mutated genes, including 4 genes that have not been previously implicated in the <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>In every case, progression to <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> was defined by the persistence of an antecedent founding clone containing 182 to 660 <z:hpo ids='HP_0001428'>somatic mutations</z:hpo> and the outgrowth or emergence of at least one subclone, harboring dozens to hundreds of new mutations </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> founding clones and subclones contained at least one mutation in a coding gene </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Nearly <z:hpo ids='HP_0000001'>all</z:hpo> the bone marrow cells in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> and <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> are clonally derived </plain></SENT>
<SENT sid="10" pm="."><plain>Genetic evolution of <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> is a dynamic process shaped by multiple cycles of mutation acquisition and clonal selection </plain></SENT>
<SENT sid="11" pm="."><plain>Recurrent gene mutations are found in both founding clones and daughter subclones </plain></SENT>
<SENT sid="12" pm="."><plain>(Funded by the National Institutes of Health and others.) </plain></SENT>
</text></document>